Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Could Warner Chilcott Plc (WCRX) Receive a Higher Bid?

Warner Chilcott PlcRecently, Actavis Inc (NYSE:ACT) announced that it would acquire Warner Chilcott Plc (NASDAQ:WCRX) for around $8.5 billion in total consideration. Since the beginning of the year, Warner Chilcott has risen from around $12 per share to nearly $20 per share. Is a $5 billion deal a fair offering price for Warner Chilcott Plc (NASDAQ:WCRX)? Let’s find out.

Actavis and Warner Chilcott’s snapshot

Actavis Inc (NYSE:ACT) provides 250 generic pharmaceutical product families and more than 40 brand pharmaceutical products in more than 60 countries around the world, operating in three main business segments: Actavis Pharma, Actavis Inc (NYSE:ACT) Specialty Brands and Anda Distribution. Most of its revenue, $4.45 billion, was generated from the Actavis Pharma segment. The Anda Distribution segment contributed $986.4 million in sales and the Actavis Specialy Brands generated more than $482 million in revenue.

Among the three, the Actavis Inc (NYSE:ACT) Pharma segment has the highest margin at 33.3%, with the highest operating income of $1.48 billion, while the Anda Distribution segment had the lowest margin at 5.1%, with $50 million in profits. Actavis concentrates its sales into two biggest customers, Walgreen Company (NYSE:WAG) and McKesson Corporation (NYSE:MCK), accounting for 16% and 14%, respectively, of the total net sales.

Warner Chilcott Plc (NASDAQ:WCRX) is the U.S. leader in women’s healthcare, gastroenterology and dermatology, with six main product classes. The majority of its revenue, $793 million, or 31% of the total revenue, was derived from the sale of gastroenterology’s products. Osteoporosis products ranked second with $591 million in sales, or 23% of the total revenue, while the Hormonal Contraceptives products generated $544 million in sales. The company also has quite a concentrated customer base. Its three biggest customers are McKesson Corporation (NYSE:MCK) (27% of the total revenue), Cardinal Health (26%) and AmerisourceBergen (12%).

A good merger for Actavis

The merger would be a good move for Actavis Inc (NYSE:ACT) Specialty Brands to expand its footprint in gastroenterology and dermatology market, with $3 billion in annual revenue in Actavis Specialty Brands. Actavis estimated over $400 million in anticipated after-tax operational synergies, cost cutting and tax savings, which would be realized in 2014. The combined company would generate strong operating cash flow with only less than 3 times debt/adjusted EBITDA right after deal close. Along with a combined entity’s tax rate of around 17%, it thought the deal would generate more than 30% accretive to the 2014 non-GAAP EPS.

At around $20 per share, Warner Chilcott is worth $5 billion on the market. The market values Warner Chilcott Plc (NASDAQ:WCRX) at only 6.12 times EV/EBITDA. In contrast, Actavis Inc (NYSE:ACT) has a much higher valuation. It is trading at around $127.20 per share, with a total market cap of about 16.25 billion on the market. It is valued at as high as 15.3 times EV/EBITDA.